Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya
View/ Open
Date
2012-06Author
Chung, Michael H
Etyang, Anthony
Thiga, Joan W
Benki-Nugent, Sarah F
Kohler, Pamela K
John-Stewart, Grace C
Njoroge, Julia
McGrath, Christine J
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described. We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4T-based and 269 (15 %) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n = 236) among d4T users and 6.9 (n = 7) among ZDV users (P = 0.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P = 0.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.
Citation
Journal of NeuroVirology June 2012, Volume 18, Issue 3, pp 200-204Publisher
Department of Plant Science and Crop Protection